athenahealth Inc. (NASDAQ:ATHN) had its target price upped by Jefferies Group from $105.00 to $110.00 in a research note issued to investors on Friday. The brokerage currently has an “underperform” rating on the stock. Jefferies Group’s price target suggests a potential downside of 10.93% from the company’s previous close.
ATHN has been the topic of several other research reports. Canaccord Genuity reissued a “hold” rating and set a $142.00 price objective on shares of athenahealth in a research note on Wednesday, June 29th. Stifel Nicolaus began coverage on shares of athenahealth in a research note on Wednesday, August 31st. They set a “hold” rating on the stock. FBR & Co reduced their price objective on shares of athenahealth from $145.00 to $140.00 and set a “market perform” rating on the stock in a research note on Friday, July 22nd. Deutsche Bank AG lowered shares of athenahealth from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $165.00 to $147.00 in a research note on Friday, July 22nd. Finally, Zacks Investment Research lowered shares of athenahealth from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 12th. Four analysts have rated the stock with a sell rating, nine have assigned a hold rating and nine have assigned a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $149.95.
athenahealth (NASDAQ:ATHN) opened at 123.50 on Friday. The company has a market cap of $4.86 billion, a price-to-earnings ratio of 454.04 and a beta of 1.28. The company’s 50-day moving average is $123.71 and its 200 day moving average is $129.43. athenahealth has a 12 month low of $114.59 and a 12 month high of $170.42.
athenahealth (NASDAQ:ATHN) last issued its quarterly earnings results on Thursday, July 21st. The company reported $0.34 EPS for the quarter, missing the consensus estimate of $0.42 by $0.08. athenahealth had a return on equity of 5.16% and a net margin of 1.06%. The business had revenue of $261.90 million for the quarter, compared to analyst estimates of $274.07 million. Equities analysts forecast that athenahealth will post $1.77 earnings per share for the current fiscal year.
In related news, VP Karl Stubelis sold 928 shares of the company’s stock in a transaction dated Wednesday, September 7th. The shares were sold at an average price of $123.36, for a total value of $114,478.08. Following the transaction, the vice president now directly owns 1,375 shares in the company, valued at $169,620. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director John A. Kane sold 2,875 shares of the company’s stock in a transaction dated Wednesday, July 27th. The shares were sold at an average price of $128.81, for a total transaction of $370,328.75. Following the completion of the transaction, the director now owns 10,708 shares in the company, valued at $1,379,297.48. The disclosure for this sale can be found here. 3.04% of the stock is currently owned by company insiders.
Institutional investors have recently added to or reduced their stakes in the stock. Aperio Group LLC increased its position in athenahealth by 11.6% in the first quarter. Aperio Group LLC now owns 3,429 shares of the company’s stock valued at $476,000 after buying an additional 357 shares during the period. Pacad Investment Ltd. acquired a new position in athenahealth during the first quarter valued at approximately $222,000. BlackRock Inc. increased its position in athenahealth by 273.8% in the first quarter. BlackRock Inc. now owns 4,508 shares of the company’s stock valued at $625,000 after buying an additional 3,302 shares during the period. BlackRock Group LTD increased its position in athenahealth by 23.2% in the first quarter. BlackRock Group LTD now owns 28,887 shares of the company’s stock valued at $4,008,000 after buying an additional 5,447 shares during the period. Finally, JPMorgan Chase & Co. increased its position in athenahealth by 66.7% in the first quarter. JPMorgan Chase & Co. now owns 84,834 shares of the company’s stock valued at $11,773,000 after buying an additional 33,933 shares during the period.
athenahealth, Inc is a provider of cloud-based services and mobile applications for medical groups and health systems. The Company delivers cloud-based services for revenue cycle management and medical billing, electronic health records (EHR), patient engagement, care coordination, order transmission, population health management, and clinical decision support.
Receive News & Ratings for athenahealth Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for athenahealth Inc. and related companies with MarketBeat.com's FREE daily email newsletter.